Lisocabtagene maraleucel (liso-cel) shows high response rates in heavily pretreated patients with relapsed or refractory chronic lymphocytic leukemia (CLL), with a CR/CRu rate of 60% and ORR of 83.3%.
Inflammation covertly rewires the bone marrow, enabling mutated stem cells to rise and setting the stage for future blood disease.
As therapy for chronic lymphocytic leukemia (CLL) continues to evolve, 2025 brought research, regulatory news, and expert ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback